The Supreme Court has dismissed the appeal filed by the Ministry of Food and Drug Safety’s Seoul office, maintaining a lower court's decision to suspend the ban on selling and making Botulax, Hugel's botulinum toxin.According to Hugel, the ministry’s order to ban the sales and manufacture of Botulax
In 2021, Boehringer Ingelheim’s R&D investment hit 4.1 billion euros ($4.46 billion), a new high in its 137-year history. Among them, R&D investment in human pharmaceuticals was 3.7 billion euros for over 100 products. The company aims to release up to 15 new products by 2025.Boehringer Ingelheim he
Shares of Korea United Pharm plummeted just before the Tuesday marketing closing, possibly affected by foreign investors’ recent sell-off of Korean stocks, industry sources said.The stock price of Korea United Pharm closed at 30,450 won ($24.99) on Tuesday, plunging by the daily limit of 30 percent
Therapeutic cancer vaccines are emerging as candidate drugs for major combination therapy with immune checkpoint inhibitors, and the attention is also on Korean developers of such vaccines, an industry report said.The Korea Health Industry Development Institute (KHIDI) released a report on the statu
Medytox Korea, a subsidiary of Medytox, said Tuesday that it has completed the phase 3 trial of MBA-P01, a next-generation botulinum toxin (BTX).The company has been conducting comparative studies on the efficacy and safety of MBA-P01 on 318 adults in need of moderate to severe forehead wrinkle trea
SK Chemicals said that it has signed a joint sales contract with UCB Korea for the latter's epilepsy treatment Keppra lineup (ingredient name: levetiracetam).Under the accord, UCB Korea will sell to top-tier and some general hospitals, and SK Chemicals will conduct marketing for other general hospit
MSD had expected that its pneumococcal vaccine Vaxneuvance would obtain expanded indication for children and infants by April, but the FDA recently pushed back the review date for the drug.With the possibility of the delay in the expanded indication, MSD may not be able to secure a large share in th
Daewon Pharmaceutical said Monday that the company has launched Escorten, its first proton-pump inhibitor drug.Escoten Tablet is a PPI treatment containing esomeprazole magnesium trihydrate as the main ingredient. The company started developing the drug in 2019, completed phase 1 clinical trials in
Handok said it signed a supply and distribution agreement with Incyte Corp. for pemigatinib, a cholangiocarcinoma-targeted treatment targeting the fibroblast growth factor receptor (FGFR 2), and tafasitamab, a CD19-targeted diffuse large B-cell lymphoma treatment.Under the accord, Handok will be res
Medytox said Friday it has filed a complaint with the U.S. International Trade Commission (ITC) against rival botulinum toxin (BTX) maker Hugel, alleging that the latter developed the treatment using a stolen manufacturing secret."Hugel has developed and produced a BTX product by misappropriating tr
New drug development using artificial intelligence (AI) has become a major trend in the global pharmaceutical industry, but some question the feasibility of such efforts.Industry officials said AI would help save cost and time for drug development and raise the chance of commercialization. Yet, no A
Dong-A ST's antibacterial drug Sivextro achieved sales of about 29 billion won ($23.9 million) in the U.S. last year, according to the 2021 performance data released Tuesday by Nabriva Therapeutics, the exclusive marketer of Sivextro in the U.S.Sivextro accounted for 82 percent of Nabriva's total sa
Oscotec said it signed a technology transfer agreement with Kanaph Therapeutics to acquire the exclusive global license for the latter's KNP-502, an EP2/4 dual inhibitor for treating cancer.Under the accord, Kanaph will receive a down payment of 2 billion won ($1.6 million), various milestones and r
As Roche’s Gavreto (pralsetinib) won the regulatory nod following Lilly’s Retevmo (selpercatinib) in March, the two RET (rearranged during transfection) targeted therapies are likely to compete in the Korean market.However, for the two treatments to be used for cancer patients regardless of cancer t
BMS Korea said that Revlimid (ingredient: lenalidomide), its multiple myeloma treatment, will receive insurance benefits as a combination therapy with Velcade (Ingredient: bortezomib) and dexamethasone for treating newly diagnosed multiple myeloma patients from the next month.The Ministry of Health
Curome Bioscience, a Korean bio venture, said that it received orphan drug designation (ODD) for HK-660S, a nicotinamide adenine dinucleotide (NAD+) accelerator, from the U.S. Food and Drug Administration for treating primary sclerosing cholangitis (PSC).HK-660S is undergoing phase 2 in Korea with 2
Roche Korea and the government failed to reach an agreement over the reimbursement rate of Tecentriq (atezolizumab) for the treatment of hepatocellular carcinoma (HCC) within the negotiation deadline.Roche Korea said it was actively talking with the government to win health insurance benefits, but K
Dx&Vx signed a memorandum of understanding on industry-university-research cooperation with the Hanyang Institute of Bioscience and Biotechnology (HY-IBB) on Tuesday.Under the accord, Dx&Vx and HY-IBB will jointly operate NGS (Next Generation Sequencing) equipment of the genome core and collaborate
Menarini Korea plans to introduce a new gel-type erectile dysfunction treatment in Korea.According to the industry sources on Tuesday, Futura Medical, a U.K.-based pharmaceutical company, signed an exclusive license agreement with Menarini Korea for commercializing MED3000, a gel-type erectile dysfu
Three Korean pharmaceutical companies are speeding up U.S. clinical trials to develop a new non-alcoholic steatohepatitis (NASH) treatment.NASH develops when liver tissues have inflammation due to fat accumulated in the liver regardless of alcohol intake. The disease can worsen to become cirrhosis a